Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Accenture
McKinsey
QuintilesIMS
Medtronic
Chinese Patent Office
Healthtrust
Federal Trade Commission
Colorcon

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020705

« Back to Dashboard

NDA 020705 describes RESCRIPTOR, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the RESCRIPTOR profile page.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. One supplier is listed for this compound. Additional details are available on the delavirdine mesylate profile page.
Summary for 020705
Tradename:RESCRIPTOR
Applicant:Viiv Hlthcare
Ingredient:delavirdine mesylate
Patents:1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Pharmacology for NDA: 020705
Medical Subject Heading (MeSH) Categories for 020705
Suppliers and Packaging for NDA: 020705
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705 NDA ViiV Healthcare Company 49702-209 N 49702-209-24
RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705 NDA ViiV Healthcare Company 49702-225 N 49702-225-17

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Apr 4, 1997TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength200MG
Approval Date:Jul 14, 1999TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jun 7, 2019Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 020705

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
US Department of Justice
Boehringer Ingelheim
Covington
Cerilliant
US Army
Deloitte
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.